Longitude Capital

Longitude portfolio company Vera Therapeutics, Inc. recently announced data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN) that show stabilized kidney function through 96 weeks of long-term follow-up. “We are excited to present these long-term efficacy and safety data from the ORIGIN Phase 2b study, which further demonstrate atacicept’s potential to address the underlying pathogenesis of IgAN," said Vera Founder and CEO Marshall Fordyce, M.D. "The stabilization of kidney function through two years—the longest duration of data among B cell modulators to date—positions atacicept as a potential best- and first-in-class treatment option for patients with IgAN." Learn more: https://lnkd.in/euudSjzA #atacicept #biotech #IgAN

How does the Nalu Medical, Inc. Peripheral Nerve Stimulation system help patients manage chronic pain? In a new #whitepaper, Nalu shares clinical data and key findings that demonstrate how its PNS system is advancing pain management: https://lnkd.in/gQA253Mm #ChronicPain

Longitude portfolio company Lexeo Therapeutics announced that interim data from the ongoing Phase 1/2 trial of LX1001 have been selected as a late-breaking oral presentation at this week’s CTAD Clinical Trials on Alzheimer's Disease conference in Madrid. LX1001 is an AAVrh10-based gene therapy candidate for the treatment of APOE4-homozygous Alzheimer’s disease. “APOE4-associated Alzheimer’s disease is a devastating, genetically distinct condition and despite recent therapeutic advances, patients with this genetic profile have limited effective treatment options,” said Dr. Sandi See Tai, Chief Development Officer of Lexeo Therapeutics. “We look forward to presenting new data from the first clinical trial seeking to address the underlying genetic cause of APOE4-associated Alzheimer’s disease with a targeted approach.” Read more at https://lnkd.in/eFXe-j7d #GeneTherapy #Alzheimers

Congratulations to Alpha-9 Oncology on closing its $175 Million Series C financing. Longitude is excited to continue supporting Alpha-9 as the company develops radiopharmaceuticals to meaningfully improve the treatment of people living with cancer. “Over the last few years, Alpha-9 has built a leading radiopharmaceutical company with a deep pipeline and robust infrastructure,” said Alpha-9 CEO David Hirsch, MD, PhD. “The Series C is an exciting, significant milestone for us and will greatly accelerate our growth. We are thrilled to have the backing of a top-tier investor syndicate who share our belief in the potential of radiopharmaceuticals.” Read more at https://lnkd.in/gG3qqDgg  #radiopharmaceutical #venturecapital #pharma #cancertreatment

Longitude portfolio company Cortica, a physician-led, whole-child, value-based autism care company, recently opened its first North Carolina center. "We're thrilled to welcome Raleigh-Durham families to Cortica and provide diagnostic, applied behavioral analysis, developmental therapy, medical, and counseling services, all under one roof," said Cortica CEO Neil Hattangadi, MD, MSc. "At a time when many families in the community are waiting 12 to 18 months for services, we're able to provide immediate, comprehensive support for families and prevent early intervention delays." Learn more about Cortica's work and its new Raleigh-Durham center: https://lnkd.in/gW5f2Ft9 #AutismCare

Longitude portfolio company Endogenex has enrolled its first patient in the ReCET Clinical Study, a trial assessing the safety and effectiveness of its ReCET™ System for type 2 diabetes treatment. Read more about Endogenex and its work to transform diabetes care: https://lnkd.in/eRiBVyUJ #Diabetes

Kristen Fortney, CEO and co-founder at Longitude portfolio company BioAge Labs, was recently honored as a cardiometabolic all-star by PharmaVoice. “Fortney’s breakthrough insight — that the mechanisms governing aging are linked to the pathogenesis of age-related diseases — fits neatly into the wider goals of obesity drug development, and could lead to therapies that restore body composition and boost metabolism overall," wrote PharmaVoice. Read more about BioAge and Fortney's work at the helm: https://lnkd.in/dQzracmz #MetabolicHealth #Biotech

Congratulations to 89bio CEO Rohan Palekar for being named to PharmaVoice’s list of industry leaders reshaping the pharma world! Learn more about 89bio’s work developing cardiometabolic solutions to treat diseases that affect millions: https://lnkd.in/gUkskmDc

Congratulations to Longitude portfolio company Ceribell │ AI-Powered Point-of-Care EEG on its IPO and Nasdaq listing! Ceribell is revolutionizing seizure management in acute care with its AI-powered point-of-care EEG diagnostic system. Exciting to see the team achieve this major milestone! 

Longitude portfolio company Cohere Health and MCG Health are partnering to improve the prior authorization process for providers, patients, and health plans. “MCG Health is the perfect partner to complement Cohere’s groundbreaking, AI-driven offering with industry-leading and nationally recognized clinical criteria,” said Cohere CEO Siva Namasivayam. “Our leading, proven technology innovations applied to MCG’s substantial clinical guidelines footprint will accelerate a new era of less prior authorization friction. Healthcare constituents are increasingly demanding innovative solutions that provide lower costs and faster access to care.” Read more about the partnership: https://lnkd.in/ePgJPbvw #HealthTech #artificialintelligence